Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes
Sequences of 234 complete genomes and 631 hepatitis B surface antigen genes were used to assess the worldwide diversity of hepatitis B virus (HBV). Apart from the described two subgenotypes each for… Expand
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the… Expand
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects… Expand
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H.… Expand
Hepatitis B virus resistance to nucleos(t)ide analogues.
Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos(t)ide analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to treatment failure… Expand
Toll‐like receptors, RIG‐I‐like RNA helicases and the antiviral innate immune response
The antiviral innate immune response follows the detection of viral components by host pattern recognition receptors (PRRs). Two families of PRRs have emerged as key sensors of viral infection:… Expand
Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide… Expand
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
BACKGROUND & AIMS Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a unique episomal replicative intermediate responsible for persistent infection of hepatocytes. Technical… Expand
Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine
- D. Tenney, S. Levine, +14 authors R. Colonno
- Biology, Medicine
- Antimicrobial Agents and Chemotherapy
- 1 September 2004
ABSTRACT Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TCr) hepatitis B virus (HBV). Among the patients treated in… Expand
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.
BACKGROUND & AIMS Data from clinical trials suggest a potential role for on-treatment monitoring of serum HBsAg titres during interferon-alpha (pegIFN) therapy in predicting virological responses.… Expand